Manipulation of Schlemm's effective in treating glaucoma

Article

According to Manfred Tetz and colleagues, Germany, dilation and tensioning of Schlemm's canal may be an effective, non-penetrating surgical method for the treatment of open angle glaucoma (OAG).

According to Manfred Tetz and colleagues, Germany, dilation and tensioning of Schlemm's canal may be an effective, non-penetrating surgical method for the treatment of open angle glaucoma (OAG).

The authors conducted a multicentre, prospective clinical study at three German outpatient surgical centres to determine the safety and efficacy of dilation and tensioning of Schlemm's canal during non-penetrating surgery in glaucoma patients.

A flexible microcannula was introduced into the canal, following surgical exposure, to perform viscodilation of the canal and associated collector channels. The microcannula was used, after 360 degrees of canal cannulation, to insert a 10-0 prolene suture to tension the inner wall of the canal and related trabecular meshwork. Postoperatively, subjects were examined to evaluate the anterior segment and intraocular pressure (IOP), a number of patients were also examined using high resolution ultrasound imaging of the anterior segment angle to evaluate the Schlemm's canal morphology.

To date, the results from 71 subjects have been gathered. Tensioning sutures were observed to distend the inner wall of the canal and trabecular meshwork, whilst also maintaining the canal lumen. Average IOP at six months follow up (n=26) was 14.4 mmHg with an average of 0.2 medications being used. Just four subjects reported adverse events.

Tetz and co-workers noted that viscodilation of the canal restored physiologic drainage and controlled IOP levels. Consequently, they concluded that dilation and tensioning could be an effective non-penetrating surgical method for the treatment of OAG.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.